Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing

Prostate

Volumn 48, Issue 2, 2001, Pages 122-126

  Denmeade, Samuel R ^a   Lövgren, Janita ^b,c   Khan, Saeed R ^a   Lilja, Hans ^b   Isaacs, John T ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Auto processing; Human glandular kallikrein 2 (hK2); Propeptide; Prostate cancer; Prostate specific antigen (PSA)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEINASE; TISSUE KALLIKREIN;

AMINO ACID SEQUENCE; ARTICLE; ENZYME ACTIVATION; ENZYME KINETICS; ENZYME SPECIFICITY; HYDROLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN PROCESSING;

ENZYME INDUCTION; HUMANS; HYDROLYSIS; KINETICS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; SIGNAL TRANSDUCTION; TISSUE KALLIKREINS;

EID: 0035399462     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1088     Document Type: Article

References (25)

1. Prostate-specific antigen
2. New nomenclature for the human tissue kallikrein gene family
3. The new human kallikrein gene family: Implications in carcinogenesis
4. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors
5. Semenogelin, the predominant protein in human semen
6. The chymotrypsin-like activity of human prostate-specific antigen γ-seminoprotein
7. Production of recombinant PSA and hk2 and analysis of their immunologic cross-reactivity
8. 2+ and extracellular protease inhibitors
9. Isolation of prostatic kallikrein hK2, also know as hGK-1, in human seminal plasma
10. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids
11. Ala217 is important for the catalytic function and autoactivation of prostate-specific kallikrein 2
12. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker
13. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum
14. Human glandular kallikrein 2 (hK2) expression in prostate adenocarcinoma and lymph node metastases
15. Characterization of the precursor of prostate-specific antigen
16. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2
17. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2
18. Androgen-sensitive human prostate cancer cells, LNCaP, produce both N-terminally mature and truncated prostate-specific antigen isoforms
19. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator
20. Human kallikrein 2 (hK2) inactivates and complexes with plasminogen activator inhibitor-1 (PAI-1)
21. Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels
22. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate specific antigen
23. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells
24. Characterization and processing of prostate-specific antigen (hK3) and human glandular kallikrein 2 (hK2) secreted by LNCaP cells
25. Enzymatic-activation of a doxorubicin-peptide prodrug by prostate-specific antigen